burger

A pharmaceutical company
specialising in biological
medicinal products

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€ 458 M IN TURNOVER

IN 2021

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

All news

3:24

THE NEW LFB ARRAS PLANT, January 2022

3:32

Part 1: three years of LFB transformation

2:38

Part 2 : the new Momentum

3:13

Part 3 : LFB's values

All videos

2022 LFB corporate Brochure: discover the Denis Delval edito in video

Discover the new LFB CSR Charter

The new LFB Arras plant in video

LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins in France

Interview with Denis Delval

Bruno de Miribel joins LFB

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

3:24

THE NEW LFB ARRAS PLANT, January 2022

there is 3 months

3:13

Part 3 : LFB's values

there is 12 months

2:38

Part 2 : the new Momentum

there is 12 months

3:32

Part 1: three years of LFB transformation

there is 1 year